Reviewing DBV TECHNOLOGIE/S (DBVT) & Aerie Pharmaceuticals (AERI)

DBV TECHNOLOGIE/S (NASDAQ:DBVT) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares DBV TECHNOLOGIE/S and Aerie Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DBV TECHNOLOGIE/S N/A N/A N/A
Aerie Pharmaceuticals N/A -91.80% -63.63%

Institutional and Insider Ownership

44.1% of DBV TECHNOLOGIE/S shares are owned by institutional investors. 15.3% of DBV TECHNOLOGIE/S shares are owned by company insiders. Comparatively, 10.5% of Aerie Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

DBV TECHNOLOGIE/S has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Valuation and Earnings

This table compares DBV TECHNOLOGIE/S and Aerie Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV TECHNOLOGIE/S $17.17 million 34.62 -$196.14 million ($3.37) -2.97
Aerie Pharmaceuticals $24.18 million 75.58 -$232.57 million ($4.65) -8.56

DBV TECHNOLOGIE/S has higher earnings, but lower revenue than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV TECHNOLOGIE/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for DBV TECHNOLOGIE/S and Aerie Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV TECHNOLOGIE/S 1 4 3 0 2.25
Aerie Pharmaceuticals 1 0 10 0 2.82

DBV TECHNOLOGIE/S presently has a consensus target price of $15.46, suggesting a potential upside of 54.64%. Aerie Pharmaceuticals has a consensus target price of $79.18, suggesting a potential upside of 98.95%. Given Aerie Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Aerie Pharmaceuticals is more favorable than DBV TECHNOLOGIE/S.

Summary

DBV TECHNOLOGIE/S beats Aerie Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.